<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015361</url>
  </required_header>
  <id_info>
    <org_study_id>HR7056-204</org_study_id>
    <nct_id>NCT05015361</nct_id>
  </id_info>
  <brief_title>A Trial of Efficacy and Safety of Remimazolam Tosilate for Injection in Local Anesthesia Assisted Sedation</brief_title>
  <official_title>Efficacy and Safety of Remimazolam Tosilate for Injection in Local Anesthesia Assisted Sedation -- a Multicenter, Randomized, Single Blind, Positive Drug Parallel Controlled Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Remimazolam Tosilate for injection in local anesthesia&#xD;
      assisted sedation, and to explore the dose range of remazolam toluenesulfonate for injection&#xD;
      in local anesthesia assisted sedation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Actual">July 4, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Remimazolam Tosilate compared with Propofol Injection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to maintain target sedation as a percentage of the total study administration time.</measure>
    <time_frame>through study completion,an average of about 1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieved target sedation within 3 minutes after starting intravenous injection of load dose test drugs;</measure>
    <time_frame>3 minutes after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects receiving remedial sedation;</measure>
    <time_frame>through study completion,an average of about 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time from the start of intravenous injection of load dose test drug to the first achievement of target sedation;</measure>
    <time_frame>Time to achieve target sedation, an average of about 4 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time from stopping infusion of test drugs to reaching MOAA/S level 5 for the first time after operation</measure>
    <time_frame>Recovery time, an average of about 7 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthesiologists' satisfaction with sedation</measure>
    <time_frame>through study completion,an average of about 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of subjects' satisfaction with sedation treatment;</measure>
    <time_frame>through study completion,an average of about 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anterograde amnesia.</measure>
    <time_frame>through study completion,an average of about 1 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Local Anesthesia Assisted Sedation</condition>
  <arm_group>
    <arm_group_label>Treatment group A/B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group A: Remimazolam Tosilate Treatment group B: Remimazolam Tosilate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment group C: Propofol Injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Tosilate</intervention_name>
    <description>Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose</description>
    <arm_group_label>Treatment group A/B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Injection.</intervention_name>
    <description>Treatment group C: Propofol Injection.</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Subjects requiring local anesthesia assisted sedation&#xD;
&#xD;
          3. Male or female&#xD;
&#xD;
          4. Meet the weight standard&#xD;
&#xD;
          5. Conform to the ASA Physical Status Classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous respiratory or pulmonary diseases&#xD;
&#xD;
          2. Subjects who had received general anesthesia&#xD;
&#xD;
          3. Subjects with a history of myocardial infarction or unstable angina pectoris&#xD;
&#xD;
          4. Subjects with atrioventricular block or cardiac insufficiency&#xD;
&#xD;
          5. Subjects with a history of ischemic stroke or transient ischemic attack&#xD;
&#xD;
          6. Subjects with poor blood pressure control after medication&#xD;
&#xD;
          7. Subjects with abnormal clotting function&#xD;
&#xD;
          8. Subjects with a history of mental illness and a history of cognitive impairment&#xD;
             epilepsy&#xD;
&#xD;
          9. Subjects with a history or possibility of a difficult airway&#xD;
&#xD;
         10. Subject with a history of substance abuse and drug abuse&#xD;
&#xD;
         11. Abnormal values in the laboratory&#xD;
&#xD;
         12. Allergic to a drug ingredient or component&#xD;
&#xD;
         13. Pregnant or nursing women&#xD;
&#xD;
         14. No birth control during the specified period of time&#xD;
&#xD;
         15. Participated in clinical trials of other drugs (received experimental drugs)&#xD;
&#xD;
         16. The inestigators determined that other conditions were inappropriate for participation&#xD;
             in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

